Clinical trial
Erlotinib as First-line Treatment of Advanced Non-small Cell Lung Cancer (NSCLC)…
NCT00452075 · Rigshospitalet, Denmark, Other · Terminated
Key facts
| NCT number | NCT00452075 |
|---|---|
| Title | Erlotinib as First-line Treatment of Advanced Non-small Cell Lung Cancer (NSCLC) for Patients Unfit for Chemotherapy |
| Official title | A Phase II Study of Erlotinib and Predictive Markers as First-line Treatment of Advanced Non-small Cell Lung Cancer for Patients Unfit for Chemotherapy |
| Lead sponsor | Rigshospitalet, Denmark, Other |
| Collaborators | Hoffmann-La Roche Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | erlotinib |
| Enrollment | 24 |
| Start date | Mar 1, 2007 |
| Primary completion | Feb 1, 2010 |
| Completion | Aug 1, 2010 |
| First posted | Mar 26, 2007 |
| Last update posted | Dec 11, 2014 |
| Countries | Denmark |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: